List of bibliographic references
Number of relevant bibliographic references: 7.
List of associated KwdEn.i
Nombre de documents | Descripteur |
4 | Aged |
4 | Humans |
4 | Male |
3 | Bone Neoplasms (secondary) |
3 | Disease-Free Survival |
3 | Double-Blind Method |
3 | Prostate cancer |
3 | Prostatic Neoplasms, Castration-Resistant (drug therapy) |
3 | Prostatic Neoplasms, Castration-Resistant (mortality) |
3 | Prostatic Neoplasms, Castration-Resistant (pathology) |
3 | Time Factors |
3 | Treatment Outcome |
2 | Abiraterone |
2 | Advanced stage |
2 | Antineoplastic Agents, Hormonal (adverse effects) |
2 | Antineoplastic Agents, Hormonal (therapeutic use) |
2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
2 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
2 | Bone Neoplasms (drug therapy) |
2 | Bone Neoplasms (mortality) |
2 | Castration |
2 | Chemotherapy |
2 | Disease Progression |
2 | Drug Administration Schedule |
2 | Human |
2 | Kaplan-Meier Estimate |
2 | Metastasis |
2 | Metastatic |
2 | Middle Aged |
2 | Odds Ratio |
2 | Prednisone (therapeutic use) |
2 | Proportional Hazards Models |
2 | Resistance |
2 | Risk Factors |
1 | Abiraterone Acetate |
1 | Abiraterone Acetate (adverse effects) |
1 | Abiraterone Acetate (therapeutic use) |
1 | Acetate |
1 | Adult |
1 | Aged, 80 and over |
1 | Androgen Antagonists (therapeutic use) |
1 | Androstenes (administration & dosage) |
1 | Androstenes (adverse effects) |
1 | Androstenes (therapeutic use) |
1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
1 | Antibodies, Monoclonal, Humanized (therapeutic use) |
1 | Antineoplastic Agents (administration & dosage) |
1 | Antineoplastic Agents (therapeutic use) |
1 | Antineoplastic Agents, Hormonal (administration & dosage) |
1 | Antineoplastic Combined Chemotherapy Protocols |
1 | Biomarkers, Tumor (blood) |
1 | Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology) |
1 | Bone Density Conservation Agents (adverse effects) |
1 | Bone Density Conservation Agents (therapeutic use) |
1 | Bone Neoplasms (diagnosis) |
1 | Bone metastasis |
1 | Cancerology |
1 | Castration (methods) |
1 | Clinical Trials, Phase III as Topic |
1 | Cytochrome P-450 Enzyme Inhibitors (administration & dosage) |
1 | Cytochrome P-450 Enzyme Inhibitors (adverse effects) |
1 | Denosumab |
1 | Doubling time |
1 | Follow-Up Studies |
1 | Immunomodulator |
1 | Injections, Subcutaneous |
1 | Long term |
1 | Medicine |
1 | Multicenter Studies as Topic |
1 | Neoplasm Metastasis |
1 | Neoplasm Staging |
1 | Neoplasms, Hormone-Dependent (drug therapy) |
1 | Neoplasms, Hormone-Dependent (enzymology) |
1 | Neoplasms, Hormone-Dependent (mortality) |
1 | Neoplasms, Hormone-Dependent (pathology) |
1 | Nephrology |
1 | Prednisone (administration & dosage) |
1 | Prognosis |
1 | Prostate specific antigen |
1 | Prostate-Specific Antigen (blood) |
1 | Prostatic Neoplasms (blood) |
1 | Prostatic Neoplasms (drug therapy) |
1 | Prostatic Neoplasms (metabolism) |
1 | Prostatic Neoplasms (pathology) |
1 | Prostatic Neoplasms, Castration-Resistant (enzymology) |
1 | RANK Ligand (antagonists & inhibitors) |
1 | Randomized Controlled Trials as Topic |
1 | Retrospective Studies |
1 | Steroid 17-alpha-Hydroxylase (antagonists & inhibitors) |
1 | Steroid 17-alpha-Hydroxylase (metabolism) |
1 | Steroid Synthesis Inhibitors (adverse effects) |
1 | Steroid Synthesis Inhibitors (therapeutic use) |
1 | Survival |
1 | Survival Rate |
1 | Toxicity |
1 | Treatment |
1 | Treatment efficiency |
1 | Tumoral marker |
1 | Urology |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Matthew R. Smith"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Matthew R. Smith" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Matthew R. Smith
}}
| This area was generated with Dilib version V0.6.33. Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 | |